Immuno-Oncology | Specialty

Novel and Combination Therapies for the Treatment of Gastric Cancer

July 18th 2019

Interpretation of Data on Immunotherapy Use in Gastric Cancer

July 18th 2019

The Role of Immunotherapy in Gastric Cancer

July 18th 2019

Ramucirumab for Progressive Disease in Gastric Cancer

July 18th 2019

Place for Surgery and Poor Prognosis

July 18th 2019

Differentiating Among the Types of Surgery

July 18th 2019

Surgery Options in Locally Advanced Gastric Cancer

July 18th 2019

Trastuzumab in HER2-Positive Gastroesophageal Cancer

July 18th 2019

First-Line Therapy in HER2-Negative Gastric Cancer

July 18th 2019

Treatment in HER2-Positive Disease and Dosing Preferences

July 18th 2019

Factors Determining Initial Treatment Approach for Gastric Cancer

July 18th 2019

Molecular Testing Used for Gastric Cancer

July 18th 2019

Genetic Risk, Screening, and Diagnosis for Gastric Cancer

July 18th 2019

Introduction and Global Trends of Gastric Cancer

July 18th 2019

Immunotherapy Research Continues to Emerge in Urothelial Cancer

July 12th 2019

Robert Dreicer, MD, highlights the current state of immunotherapy in urothelial cancer and ongoing research poised to offer more information on how to broaden its effects.

Dr. Choueiri on Checkpoint Inhibitors to Treat Sarcomatoid Carcinoma

July 11th 2019

Toni Choueiri, MD, discusses the use of checkpoint inhibitors to treat patients with sarcomatoid carcinoma.

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

July 9th 2019

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.

Trial of Triplet Regimen With Cabozantinib Plus Immunotherapy Is Planned in RCC

July 7th 2019

Investigators see potential in adding targeted therapy to dual immunotherapy for intermediate- and poor-risk patients with renal cell carcinoma. In the phase III COSMIC-313 trial, investigators aim to evaluate cabozantinib, nivolumab, and ipilimumab in patients with untreated advanced RCC.

Dr. Kuzel on Immunotherapy as a Targeted Approach to Cancer

July 3rd 2019

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Maintenance Pembrolizumab Extends PFS in Metastatic Urothelial Cancer

June 27th 2019

Switch maintenance treatment with pembrolizumab improved progression-free survival in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy.